Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archderm.141.12.1513 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systemic treatments for alopecia areata: A systematic review.
Australas J Dermatol
February 2019
Sinclair Dermatology, East Melbourne, Victoria, Australia.
A range of systemic treatments are used for alopecia areata with variable evidence supporting efficacy. In this systematic review, we evaluated the evidence surrounding systemic treatments for alopecia areata, alopecia totalis and alopecia universalis. A systematic search was conducted of the peer-reviewed literature published between 1946 and March 2018 via Medline, Embase, Amed, the Cochrane Central Register of Controlled Trials, PsychINFO and Lilacs.
View Article and Find Full Text PDFA novel therapeutic paradigm for patients with extensive alopecia areata.
Expert Opin Biol Ther
August 2016
a Department of Dermatology , Icahn School of Medicine at Mount Sinai, New York , NY , USA.
Introduction: Alopecia areata (AA) is a common, T-cell mediated, hair-centered skin disease that lacks efficacious, long-term therapies for extensive disease. Systemic immune suppressants are usually used, despite their nonspecific actions, often associated with substantial side effects. Although, the Th1 pathway was suggested as pivotal in the disease, recent studies suggest that Th2, Th9, phosphodiesterase (PDE) 4, and IL-23 axes might contribute to AA pathogenesis.
View Article and Find Full Text PDFAcitretin-induced alopecia areata: a case report.
Cutan Ocul Toxicol
June 2016
Department of Dermatology, Faculty of Medicine, Goztepe Research and Training Hospital, Istanbul Medeniyet University, Istanbul , Turkey.
Alopecia areata is a common form of non-scarring hair disorder. The development of alopecia areata during anti-psoriatic treatment has been reported with the systemic therapies such as infliximab, etanercept, adalimumab, alefacept and efalizumab. Retinoid-induced alopecia areata on the eyelash and eyebrow has not been reported in the literature.
View Article and Find Full Text PDFAlefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study.
Arch Dermatol
November 2009
Department of Dermatology, New York University Medical Center, 550 First Ave, TCH-158, New York, NY 10016, USA.
Objective: To assess the efficacy of alefacept for the treatment of severe alopecia areata (AA).
Design: Multicenter, double-blind, randomized, placebo-controlled clinical trial.
Setting: Academic departments of dermatology in the United States.
Successful treatment of alopecia universalis with alefacept: a case report and review of the literature.
Cutis
May 2008
Department of Dermatology, Louisiana State University Health Sciences Center, New Orleans 70112, USA.
Alopecia universalis often responds poorly to standard therapies. We report how a novel treatment option, alefacept, was successfully used in the management of a 21-year-old woman with alopecia universalis. The patient responded with complete regrowth of scalp and body hair after a single 12-week treatment course of alefacept.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!